Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05440786 · ClinicalTrials.gov registry record · Phase 2

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

A Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
46
Enrollment target
20
Study locations

NCT05440786 is a Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 46 participants, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05440786, a Phase 2 study of Neoplasm Metastasis and Sarcoma, Ewing, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
46 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Conditions Studied

Neoplasm Metastasis Sarcoma, Ewing

Interventions

  • DRUG Temozolomide
  • DRUG Abemaciclib
  • DRUG Irinotecan

Study Locations (20)

Other

  • Charité Campus Virchow-Klinikum - Berlin
  • IRCCS Istituto Ortopedico Rizzoli - Bologna
  • Kyushu University Hospital - Fukuoka

Victoria

  • Peter MacCallum Cancer Centre - Melbourne
  • Royal Children's Hospital - Melbourne

Barcelona [Barcelona]

  • Hospital Universitari Vall d'Hebron - Barcelona
  • Hospital Sant Joan de Déu - Esplugues de Llobregat

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • The Regents of the University of California - Los Angeles (UCLA Pediatrics) - Los Angeles

Indiana

  • Riley Hospital for Children at Indiana University Health - Indianapolis

Missouri

  • Washington University - St Louis

Rhode Island

  • Lifespan Cancer Institute - Providence

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2022-09-20
Est. Completion 2028-09
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05440786

The ClinicalTrials.gov registry entry for NCT05440786 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (89% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.

NCT05440786 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Victoria, Barcelona [Barcelona].

Frequently Asked Questions

What is clinical trial NCT05440786 about?

NCT05440786 is a clinical study titled "CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma". The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatmen...

What is the current status of trial NCT05440786?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2022-09-20. Estimated completion is 2028-09.

What conditions does trial NCT05440786 study?

This clinical trial studies the following conditions: Neoplasm Metastasis, Sarcoma, Ewing.

What interventions are being tested in trial NCT05440786?

The interventions under investigation include: Temozolomide (DRUG), Abemaciclib (DRUG), Irinotecan (DRUG).

Who is sponsoring clinical trial NCT05440786?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05440786 being conducted?

This trial has 20 study locations across Arizona, California, Indiana, Missouri, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Metastasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm Metastasis

All registered trials for this condition

Sarcoma, Ewing

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.